Glasgow Prognostic Score Shows Promise in Predicting Small Cell Lung Cancer Survival

According to the findings of the study, in patients with small cell lung cancer who were given first-line atezolizumab in addition to carboplatin and etoposide, Glasgow prognostic score appeared to be associated with survival.

No biomarkers are accessible to foresee viability of first-line treatment with atezolizumab (Tecentriq, Genentech) — an enemy of PD-L1 immunizer — in addition to carboplatin and etoposide for patients with little cell cellular breakdown in the lungs, as per concentrate on foundation.

Satoshi Wasamoto, MD, of the division of respiratory medication at Saku General Hospital Advanced Care Center in Japan, and associates assessed whether certain factors predicted adequacy of the regimen for patients with extensive-disease small cell lung cancer.

Those factors included Glasgow prognostic score — a cumulative measure in light of C-reactive protein and egg whites that demonstrates foundational fiery reaction — as well as BMI and neutrophil-to-lymphocyte proportion.

From August 2019 to May 2021, 84 patients treated at nine Japanese hospitals were the subject of the study.

PFS and OS differences were evaluated using Kaplan–Meier and Cox proportional hazard models by the researchers.

The outcomes revealed a response rate of 72.6% (95 percent CI, 63-82.1), with a median PFS of 5.4 months (95 percent CI, 4.9-5.9) and OS of 15.4 months (95 percent CI, 11.4-16.8).

After receiving atezolizumab, carboplatin, and etoposide as first-line therapy, Glasgow prognostic score independently predicted outcomes.

Patients with positive scores (0 or 1) accomplished fundamentally longer PFS (5.8 months versus 3.8 months; P =.0005) and OS (6.5 versus 8.4 months; P .0001) than individuals with low scores (2).

“This is the first analysis to evaluate the association between the [Glasgow prognostic score, neutrophil-to-lymphocyte ratio and BMI] and the treatment effectiveness of survival among patients receiving first-line atezolizumab plus carboplatin and etoposide therapy for [small cell lung cancer],” Wasamoto and colleagues wrote. “[Glasgow prognostic score] was significantly associated with the PFS and OS rates, suggesting that [it] might be useful for evaluating therapeutic outcomes in these patients.”

The researchers wrote that additional large-scale studies are required to determine if the findings of this analysis can be applied to other cohorts of patients with small cell lung cancer.